KETOROLAC-INDUCED ACUTE-RENAL-FAILURE AND HYPERKALEMIA - REPORT OF 3 CASES

Ketorolac tromethamine (Toradol, Syntex Laboratories Inc, Pale Alto, C A) is a new nonsteroidal anti-inflammatory drug widely used in emergen cy departments and during the postoperative period because of its pote nt analgesic effects and lack of central nervous system activities. We present three new cases of acute renal failure and hyperkalemia secon dary to ketorolac. All patients had at least one risk factor making th em prone to the development of acute renal failure secondary to the no nsteroidal anti-inflammatory drugs. In all patients, acute renal failu re developed after a moderate dose of ketorolac was administered for t he management of postsurgical pain. Acute renal failure and hyperkalem ia were transient, and improved after discontinuation of ketorolac tre atment. (C) 1994 by the National Kidney Foundation, Inc.